Abstract | OBJECTIVE: METHODS: Markov models were developed for the following populations: diabetics, patients with chronic or end stage kidney disease, healthcare workers and international travelers to countries with high HBV infection prevalence. Hepatitis B disease progression was modeled using 11 health states: seroprotected, susceptible, acute infection, chronic infection, fulminant hepatic failure, compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, liver transplant, post-transplant care, and death. Seroprotection rates were obtained from two phase 3 clinical trials comparing HEPLISAV with Engerix-B and ranged across various populations from 89-96% for HEPLISAV and 62-81% for Engerix-B. Higher vaccination completion rates were assumed for HEPLISAV compared with Engerix-B given that fewer doses of HEPLISAV are required in a shorter period of time to achieve seroprotection for the evaluated populations. Each cycle length after the first year in the model was 1-year. All future costs and benefits were discounted at 3%. A lifetime analysis and a U.S. payer perspective were used. RESULTS: HEPLISAV has a favorable cost-effectiveness profile with incremental cost effectiveness ratios <$25,000 across all populations studied. In the patients with chronic or end stage kidney disease, HEPLISAV was the dominant option and was cost-saving compared with Engerix-B. The cost of vaccine, regimen completion rates, and seroprotection rates were the sensitive variables in the models. CONCLUSIONS: HEPLISAV is a cost-effective option to provide high rates of seroprotection and early seroprotection across a range of populations from health care workers to patients with chronic or end stage kidney disease.
|
Authors | Renee Kim Kuan, Robert Janssen, William Heyward, Sean Bennett, Robert Nordyke |
Journal | Vaccine
(Vaccine)
Vol. 31
Issue 37
Pg. 4024-32
(Aug 20 2013)
ISSN: 1873-2518 [Electronic] Netherlands |
PMID | 23707166
(Publication Type: Comparative Study, Journal Article)
|
Copyright | Copyright © 2013 Elsevier Ltd. All rights reserved. |
Chemical References |
- Engerix-B
- Hepatitis B Vaccines
|
Topics |
- Adolescent
- Adult
- Aged
- Cost-Benefit Analysis
- Diabetes Mellitus
(economics, virology)
- Health Personnel
- Hepatitis B
(prevention & control)
- Hepatitis B Vaccines
(administration & dosage, economics, therapeutic use)
- Humans
- Kidney Failure, Chronic
(economics, virology)
- Markov Chains
- Middle Aged
- Models, Economic
- Models, Theoretical
- Probability
- Renal Insufficiency, Chronic
(economics, virology)
- Young Adult
|